Elkhorn Partners Limited Partnership Cardiff Oncology, Inc. Transaction History

Elkhorn Partners Limited Partnership

$156 Million
Q3 2024

A detailed history of Elkhorn Partners Limited Partnership transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Elkhorn Partners Limited Partnership holds 45,000 shares of CRDF stock, worth $181,350. This represents 0.08% of its overall portfolio holdings.

Number of Shares

45,000

Previous 41,000 9.76%

Holding current value

$181,350

Previous $91,000 31.87%

% of portfolio

0.08%

Previous 0.06%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.05 - $2.77 $8,200 - $11,080	4,000 Added 9.76%	45,000 $120,000
Q2 2024 Aug 12, 2024	BUY	$2.22 - $5.89 $4,440 - $11,780	2,000 Added 5.13%	41,000 $91,000
Q1 2024 May 16, 2024	BUY	$1.46 - $5.91 $56,940 - $230,490	39,000 New	39,000 $208,000
Q4 2023 Feb 13, 2024	BUY	$0.96 - $1.55 $19,680 - $31,775	20,500 Added 45.56%	65,500 $97,000
Q3 2023 Nov 13, 2023	SELL	$1.38 - $2.18 $2,760 - $4,360	-2,000 Reduced 4.26%	45,000 $63,000
Q2 2023 Aug 14, 2023	BUY	$1.37 - $1.95 $16,440 - $23,400	12,000 Added 34.29%	47,000 $69,000
Q1 2023 May 12, 2023	BUY	$1.45 - $2.09 $8,108 - $11,687	5,592 Added 19.02%	35,000 $58,000
Q4 2022 Feb 14, 2023	BUY	$1.22 - $1.66 $5,011 - $6,819	4,108 Added 16.24%	29,408 $41,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $2,310 - $4,815	1,500 Added 6.3%	25,300 $39,000
Q2 2022 Aug 12, 2022	BUY	$1.17 - $2.61 $5,616 - $12,528	4,800 Added 25.26%	23,800 $52,000
Q1 2022 May 10, 2022	BUY	$2.11 - $7.25 $3,587 - $12,325	1,700 Added 9.83%	19,000 $47,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $19,684 - $27,512	3,800 Added 28.15%	17,300 $104,000
Q3 2021 Nov 12, 2021	BUY	$5.01 - $7.58 $37,575 - $56,850	7,500 Added 125.0%	13,500 $90,000
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $31,255 - $47,187	4,700 Added 361.54%	6,000 $40,000
Q1 2021 May 11, 2021	BUY	$9.1 - $19.57 $4,186 - $9,002	460 Added 54.76%	1,300 $12,000
Q4 2020 Feb 12, 2021	SELL	$12.02 - $24.71 $1,923 - $3,953	-160 Reduced 16.0%	840 $15,000
Q3 2020 Nov 16, 2020	SELL	$4.25 - $14.19 $27,888 - $93,114	-6,562 Reduced 86.78%	1,000 $14,000
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.1 $5,898 - $38,566	7,562 New	7,562 $38,000

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.3M

Call Options Held

813K

Put Options Held

91.1K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $175M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Elkhorn Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Elkhorn Partners Limited Partnership with notifications on news.

Account

Elkhorn Partners Limited Partnership Cardiff Oncology, Inc. Transaction History